

















httpCoronary revascularization induces a shift from
cardiac toward noncardiac mortality without
improving survival in vascular surgery patients
Klaas H. J. Ultee,a Ellen V. Rouwet, MD, PhD,a Sanne E. Hoeks, PhD,b Felix van Lier, MD, PhD,b
Frederico Bastos Gonçalves, MD,a,c Eric Boersma, PhD,d Robert Jan Stolker, MD, PhD,b and
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Objective: Although evidence has shown that ischemic heart disease (IHD) in vascular surgery patients has a negative
impact on the prognosis after surgery, it is unclear whether directed treatment of IHD may inﬂuence cause-speciﬁc and
overall mortality. The objective of this study was to determine the prognostic implication of coronary revascularization
(CR) on overall and cause-speciﬁc mortality in vascular surgery patients.
Methods: Patients undergoing surgery for abdominal aortic aneurysm, carotid artery stenosis, or peripheral artery disease
in a university hospital in The Netherlands between January 2003 and December 2011 were retrospectively included.
Survival estimates were obtained by Kaplan-Meier and Cox regression analysis.
Results: A total of 1104 patients were included. Adjusted survival analyses showed that IHD signiﬁcantly increased the
risk of overall mortality (hazard ratio [HR], 1.50; 95% conﬁdence interval, 1.21-1.87) and cardiovascular death (HR,
1.93; 95% conﬁdence interval, 1.35-2.76). Compared with those without CR, patients previously undergoing CR had
similar overall mortality (HR, 1.38 vs 1.62; P [ .274) and cardiovascular mortality (HR, 1.83 vs 2.02; P [ .656).
Nonrevascularized IHD patients were more likely to die of IHD (6.9% vs 35.7%), whereas revascularized IHD patients
more frequently died of cardiovascular causes unrelated to IHD (39.1% vs 64.3%; P [ .018).
Conclusions: This study conﬁrms the signiﬁcance of IHD for postoperative survival of vascular surgery patients. CR was
associated with lower IHD-related death rates. However, it failed to provide an overall survival beneﬁt because of an increased
rate of cardiovascular mortality unrelated to IHD. Intensiﬁcation of secondary prevention regimens may be required to
prevent this shift toward non-IHD-related death and thereby improve life expectancy. (J Vasc Surg 2015;61:1543-9.)A number of reports have shown that long-term sur-
vival in patients undergoing vascular surgery procedures
is as low as 25% after 10 years.1 Cardiovascular causes
account for the majority of early and late mortality after
vascular surgery, surpassing 60%.2 It is well known that
patients undergoing vascular surgery are frequently affected
by coronary artery disease, symptomatic or not.3 Because
the presence of ischemic heart disease (IHD) is associated
with postoperative morbidity and mortality after noncar-
diac vascular surgery, IHD has been the subject of
numerous studies regarding survival, preoperative evalua-
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://dx.doi.org/10.1016/j.jvs.2015.01.033has shown that IHD in vascular surgery patients has a nega-
tive impact on the prognosis after surgery, it is unclear
whether this is solely due to IHD-related death or due to
non-IHD-related mortality risks as well.4,5
In an attempt to improve postoperative survival, several
studies have investigated the effectiveness of coronary
revascularization (CR) on the prognosis of patients under-
going noncardiac interventions.6-14 The interpretation of
these studies in terms of survival beneﬁts is hampered by
relatively short follow-up periods, small sample sizes, or
heterogeneity within the studied population regarding
patient and procedural risks. Retrospective data suggested
that prior coronary bypass surgery was associated with a
reduction of 30-day myocardial infarction and death rates.6
However, subsequent randomized trials demonstrated that
CR before vascular surgery does not improve survival.7,8
In light of these results and the systemic nature of
atherosclerotic disease, we hypothesized that long-term sur-
vival will be similar between IHD patients with CR and IHD
patients without CR because of a shift from IHD-related
toward non-IHD-related mortality.15-17 The objective of
this study was to determine the prognostic implication of
IHD and CR on long-term overall and cardiovascular mor-
tality in patients undergoing vascular surgery.
METHODS
Patients. Patients undergoing elective open or endo-
vascular surgery under general or locoregional anesthesia1543
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peripheral artery disease in the Erasmus University Medical
Center between January 2003 and December 2011 were
retrospectively included. Identiﬁcation was done with the
use of operation codes and surgical reports. Because we
were interested in the effect of IHD and prior CR on pro-
cedures that are accompanied by severe cardiac stress,
patients undergoing percutaneous procedures (ie, percuta-
neous endovascular aneurysm repair, carotid artery stent-
ing, and lower extremity revascularization) or procedures
performed under local anesthesia were not included in
this study. When a patient underwent multiple vascular
procedures within the study period, the ﬁrst operation in
this period was deﬁned as the index operation, and survival
was assessed from that moment onward. Baseline charac-
teristics were obtained from hospital records and included
age, gender, cardiac history, other comorbidities, smoking
status (current, former, or never), and body mass index
(BMI). Patients were grouped according to their cardiac
status before the index operation. IHD was considered if
one of the following was present: reference to previous car-
diac ischemic events in cardiology notes, prior coronary
intervention, or evidence of myocardial ischemia in provoc-
ative preoperative tests (dobutamine stress echocardiogra-
phy or myocardial scintigraphy). CR was deﬁned as
coronary artery bypass graft (CABG) surgery or percuta-
neous coronary intervention (PCI) at any time before the
index vascular operation. Treatment indications for CR
were in accordance with the American Heart Association
guidelines (Appropriateness Criteria for Coronary Revascu-
larization). Institutional approval for this study was
obtained, and no informed consent was required according
to local directives for retrospective studies. The study com-
plies with the Helsinki Declaration on research ethics.
Deﬁnitions. Diabetes mellitus was recorded if diabetes
was mentioned in the medical history or if patients used in-
sulin or oral antidiabetics. Hypertension was deﬁned as
blood pressure >140/90 mm Hg or use of antihyperten-
sive medication. A history of cancer was deﬁned as past
or current malignant neoplastic disease, except for basal
cell carcinoma. Renal insufﬁciency was deﬁned as an esti-
mated glomerular ﬁltration rate <60 mL/min as calculated
from preoperative serum creatinine levels using the Modi-
ﬁcation of Diet in Renal Disease formula. Smoking status
and BMI were derived from the medical records.
Follow-up. Survival status was obtained by inquiry of
the civil registry. The latest date of follow-up was consid-
ered December 31, 2012.
Cause of death. Data regarding the causes of death
were obtained from the Dutch Central Bureau of Statistics
(CBS). A database containing all relevant patient character-
istics from the hospital records was anonymized and
imported into the CBS and was subsequently linked to
the Dutch death registries. Because of CBS regulation,
data analysis was performed only by authorized researchers
(K.U., F.B.G.) in a secure environment at the CBS head
ofﬁce. Before data were approved to be used for publica-
tion purposes, all output was independently checked forprivacy violations by two separate reviewers. The cause of
death was deﬁned as the cause for the initial health deteri-
oration that subsequently resulted in death. This approach
is similar to the strategy employed for the overall Dutch
population death registrations and reports. Autopsy was
not regularly performed. The causes of death were grouped
according to the International Classiﬁcation of Diseases,
Tenth Revision. The following codes were used: for cardio-
vascular death, I10-I79; for IHD-related death, I20-I25,
I50; and for non-IHD cardiovascular death, I10-I19,
I26-I49, I51-I79 (Supplementary Table, online only).
Because IHD is the principal etiology of heart failure, death
due to heart failure-related causes was classiﬁed as
IHD-related death.18,19
End points. The primary end points were long-term
overall and cardiovascular mortality. Secondary end
points were IHD-related and non-IHD-related cardiovas-
cular mortality.
Statistical methods. Baseline characteristics were
described as counts and percentages (dichotomous
variables) or means and standard deviations (continuous
variables). Differences at baseline were determined by Pear-
son c2 analysis and one-way analysis of variance testing,
where appropriate. For survival analyses, patients were
grouped according to their cardiac medical history.
Patients’ overall survival was initially assessed by Kaplan-
Meier analyses. Cox proportional hazards models were
constructed to study the impact of IHD and the inﬂuence
of invasive treatment on overall and cardiovascular survival
in an adjusted manner. Multivariate analyses included
demographics (ie, age and gender), comorbidities (ie,
diabetes, hypertension, a history of cancer, renal insufﬁ-
ciency, and BMI), and behavioral risk factors (ie, smoking).
To determine the prognostic implications of invasive and
noninvasive treatment strategies for IHD (ie, CABG or
PCI), the overall IHD group was subdivided into a non-
CR group and a CR group. The non-IHD group was
designated the reference category for the Cox regression
analyses. Differences in cardiovascular death distribution
(ie, different proportions of IHD-related and non-IHD-
related death) were tested with the use of c2 analyses. All
tests were two sided, and signiﬁcance was considered a
P value < .05. Statistical analysis was performed with the
IBM SPSS Statistics 20 (IBM Inc, Chicago, Ill).
RESULTS
Between January 2003 and December 2011, a total of
1107 patients received surgical treatment for abdominal
aortic aneurysm, carotid artery stenosis, or peripheral artery
disease. Three patients (0.3%) were excluded because of
unobtainable follow-up due to emigration. Among the
resulting 1104 patients, 499 (45.2%) had a history of
IHD. Within the IHD group, CR was performed preoper-
atively in 245 cases (22.2%).
Baseline characteristics. Baseline characteristics per
study group (ie, non-IHD, non-CR IHD, and CR IHD)
are listed in Table I. Vascular surgical patients with IHD
were older, were more frequently of male gender, and had
Table I. Baseline characteristics
Variable Non-IHD (n ¼ 605) Non-CR IHD (n ¼ 254) CR IHD (n ¼ 245) P value
Demographics
Female gender 174 (29) 47 (19) 36 (15) <.001
Age, years 67.4 (610.2) 70.0 (69.6) 69.4 (69.3) .001
Prior medical history
Diabetes mellitus 112 (19) 65 (26) 67 (27) .006
History of cancer 98 (16) 45 (18) 41 (17) .868
Peripheral arterial occlusive disease 251 (41) 108 (43) 123 (50) .062
Renal insufﬁciency 126 (21) 76 (30) 82 (33) <.001
Cerebrovascular disease 238 (39) 100 (39) 94 (38) .962
Hypertension 375 (62) 190 (75) 190 (78) <.001
History of vascular interventions 133 (22) 64 (25) 63 (26) .406
IHD Characteristics
Myocardial infarction 0 186 (73) 189 (77) d
Angina 0 91 (36) 202 (83) d
CABG/PTCA 0 0 245 (100) d
Environmental risk factors
Smoking 257 (43) 97 (38) 75 (31) .005
BMI, kg/length2 25.7 (64.1) 26.2 (64.3) 26.9 (4.1) .001
BMI, Body mass index; CABG, coronary artery bypass graft; CR, coronary revascularization (ie, CABG or PTCA); IHD, ischemic heart disease; PTCA,
percutaneous transluminal coronary angioplasty.
Baseline characteristics are described as counts and percentages (dichotomous variables) or means and standard deviations (continuous variables).









All cause 164a 108 91
Cancer 54 (33.1) 23 (21.3) 20 (22.0)
Cardiovascular 53 (32.5) 46 (42.6) 42 (46.2)
IHD related 13 (8.0) 28 (25.9) 15 (16.5)
Non-IHD cardiovascular 40 (24.5) 18 (16.7) 27 (29.7)
Cerebrovascular disease 14 (8.6) <5 (<4.6)b <5 (<5.5)
Other arterial disease 17 (10.4) 13 (12.0) 17 (18.7)
Non-IHDc 6 (3.7) <5 (<4.6) 6 (6.6)
Otherd <5 (<3.1) <5 (<4.6) <5 (<5.5)
COPD 10 (6.1) <5 (<4.6) 5 (5.5)
Digestive system 10 (6.1) <5 (<4.6) <5 (<5.5)
Other causes 36 (22.1) 32 (29.6) 22 (24.2)
COPD, Chronic obstructive pulmonary disease; CR, coronary revasculari-
zation; IHD, ischemic heart disease.
Percentages are relative to the total obtained deaths per study group.
aCause of death was obtained for 163 of 164 patients (99.3%).
bNumbers <5 were not provided to protect privacy.
cFor example, valvular heart disease and cardiomyopathy.
dHypertensive and pulmonary circulatory disease.
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diabetes, renal insufﬁciency, and hypertension were more
common among patients with IHD. Finally, current
smoking was more frequently observed among non-IHD
patients.
Overall mortality. During a median follow-up of
4.1 years (interquartile range, 2.3-5.9), 164 (27.1%), 108
(42.5%), and 91 (37.1%) deaths occurred in the non-IHD,
non-CR IHD, and CR IHD groups, respectively
(Table II). Kaplan-Meier analyses showed a signiﬁcant
difference in the postoperative prognosis between non-
IHD and IHD patients, with an expected survival at
5 years of 74% and 62%, respectively (P < .001; Fig 1).
There was no signiﬁcant difference in survival between
IHD patients without CR and IHD patients with CR (60%
and 62% at 5 years for non-CR and CR IHD groups,
respectively; P ¼ .167). IHD was conﬁrmed as an inde-
pendent risk factor for all-cause mortality in Cox regression
analysis compared with vascular surgical patients without a
history of IHD (hazard ratio [HR], 1.50; 95% conﬁdence
interval [CI], 1.21-1.87; Table III). Regarding survival for
the groups separately, compared with the non-IHD group,
the non-CR IHD group (HR, 1.62; 95% CI, 1.26-2.08)
and the CR IHD group (HR, 1.38; 95% CI, 1.05-1.80)
were burdened by additional survival hazards. However,
there was no signiﬁcant difference in overall survival
between the revascularized and the nonrevascularized IHD
groups (P ¼ .274).
Cardiovascular mortality. Causes of death could be
obtained for all but one patient (99.7%). Cardiovascular dis-
ease was reported as the cause of death in 53 cases (32.5%)
in the non-IHD group and in 46 cases (42.6%) and 42 cases
(46.2%) in the non-CR and CR IHD groups, respectively
(Table II). Adjusted analysis showed that patients withIHD were at higher risk of cardiovascular death compared
with patients without IHD (HR, 1.93; 95% CI, 1.35-2.76;
Table III). Both the nonrevascularized group (HR, 2.02;
95% CI, 1.34-3.04) and the revascularized group (HR,
1.83; 95% CI, 1.19-2.81) had an increased risk of cardio-
vascular death compared with the non-IHD group.
Equivalent to overall survival, cardiovascular survival be-
tween the non-CR and CR groups was similar (P ¼ .656).
IHD-related and non-IHD-related cardiovascular
mortality. IHD-related death occurred 13 times (8.0%) in
the non-IHD group during the follow-up period. In the
Fig 1. Kaplan-Meier analyses for overall survival. CR, Coronary
revascularization; IHD, ischemic heart disease.
Table III. Cox regression analyses for overall and
cardiovascular mortality
Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Overall death
Overall IHD 1.64 1.33-2.01 <.001 1.50 1.21-1.87 <.001
Non-CR 1.80 1.41-2.29 <.001 1.62a 1.26-2.08 <.001
CR 1.48 1.15-1.92 .003 1.38a 1.05-1.80 .019
Cardiovascular death
Overall IHD 2.24 1.59-3.15 <.001 1.93 1.35-2.76 <.001
Non-CR 2.36 1.59-3.50 <.001 2.02b 1.34-3.04 .001
CR 2.12 1.41-3.18 <.001 1.83b 1.19-2.81 .006
CI, Conﬁdence interval; HR, hazard ratio; IHD, ischemic heart disease.
HRs for the two IHD groups separately were established in a model with
the non-IHD group as reference category.
aOverall survival between the non-CR and the CR IHD groups did not
differ (P ¼ .274).
bCardiovascular survival between the non-CR and the CR IHD groups did
not differ (P ¼ .656).
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IHD-related death was determined in 28 (25.9%) and 15
(16.5%) cases, respectively (Table II, Fig 2). Death due to
cardiovascular causes other than IHD was ascertained in 40
(24.5%), 18 (16.7%), and 27 (29.7%) cases. The distribu-
tion of the cardiovascular cause of death subgroups, IHD
related and non-IHD related, was signiﬁcantly different
between the non-IHD and the non-CR IHD groups.
Patients with a history of IHD were more likely to die of
IHD-related causes, whereas the majority of cardiovascular
death among non-IHD patients was unrelated to coronary
artery disease (P < .001). No signiﬁcant divergences were
found in the cardiovascular death distributions between the
non-IHD and the CR IHD groups (P ¼ .235). The dis-
tribution between nonrevascularized and revascularized
IHD patients, however, differed signiﬁcantly. Cardiovas-
cular death in the non-CR IHD group was predominantlydue to IHD-related causes, whereas the majority of car-
diovascular death among revascularized patients was due to
non-IHD-related disease (P ¼ .018).
DISCUSSION
The results of this study conﬁrm that prior IHD is a
signiﬁcant prognostic factor for long-term overall and car-
diovascular survival after vascular surgery. Interestingly,
patients with previous CR had similar total cardiovascular
mortality but proportionally less ischemic cardiac-related
deaths compared with patients with a history of IHD but
no prior revascularization. However, prior CR did not pro-
vide a survival beneﬁt for patients with IHD. This indicates
that coronary intervention had an impact on the occur-
rence of subsequent cardiac events but failed to provide
protection for cardiovascular death in general.
Our ﬁndings are in line with the study by Back et al,12
who showed that although perioperative cardiac factors are
the primary determinants of life expectancy, patients with a
history of CR did not have a better survival after major
arterial reconstruction. In addition, the Coronary Artery
Revascularization Prophylaxis (CARP) and DECREASE
(Dutch Echocardiographic Cardiac Risk Evaluation
Applying Stress Echo)-V trials demonstrated that even pre-
operative CR in patients with extensive myocardial
ischemia on preoperative cardiac testing failed to improve
postoperative survival compared with best medical treat-
ment alone in patients undergoing elective vascular sur-
gery.7-9,20 These studies formed the basis for the current
standpoint that CR before major noncardiac surgery
should not routinely be performed.21
As hypothesized, overall mortality and the death rate
distribution among the main categories, including cardio-
vascular and cancer-related death, were similar in the
non-CR and CR IHD groups. Further, we found that car-
diovascular death in patients with established IHD who
had not been treated for coronary stenosis by CABG or
PCI was most frequently due to ischemic cardiac events.
However, those who underwent prior coronary treatment
more often died of noncardiac ischemic events, the major-
ity of which were related to peripheral arterial rather than
cerebrovascular disease. Thus, in spite of the impact on car-
diac events, treatment of IHD induces a shift in the cause,
rather than providing protection against cardiovascular
death. Such a shift in mortality from IHD-related toward
non-IHD-related death implicates that a history of IHD
in vascular surgery patients should be regarded as a sign
of advanced atherosclerotic disease. This is in agreement
with several previous studies showing that vascular patients
are often burdened by advanced atherosclerotic disease,
whether or not they are symptomatic, in multiple vascular
beds.22,23 Also, it has been shown that the rates of ischemic
events in other vascular beds are higher in vascular patients
with a history of IHD compared with those without.24-26
In view of the risks conferred by advanced atheroscle-
rotic disease, intensiﬁcation of cardiovascular risk manage-
ment may be a potential means to reduce noncardiac
cardiovascular health hazards and to improve postoperative
Fig 2. Proportions of speciﬁc cardiovascular death causes among the different study groups. Percentages are relative to
the total cardiovascular deaths per study group. CR, Coronary revascularization; IHD, ischemic heart disease.
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tiveness of secondary prevention measures for reducing
overall and cardiovascular death is well established, studies
have demonstrated that adherence to the guidelines
is <60%.27 A lack of knowledge and the attitude of both
patients and physicians have been implicated in playing a
causal role.28,29 Therefore, improving the attitude of
patients and physicians regarding the importance of athero-
thrombotic risk and secondary prevention is worthwhile. In
addition to stimulating guideline adherence, stricter man-
agement of the cardiovascular risk factors should be consid-
ered. For example, tight control of blood pressure (ie,
#130-135 mm Hg), as opposed to relaxed control (ie,
#140 mm Hg), might be associated with a reduction in
cardiovascular morbidity and mortality.30,31 Moreover,
lowering blood pressure by as little as 10 mm Hg has
been reported to reduce the lifetime risk for cardiovascular
and stroke-related death by 25% to 40%.32 Similar associa-
tions have been found for both blood glucose and lipid
levels.33-35
The limitations of this study are inherent to its retro-
spective nature. Because all symptomatic IHD patients
were grouped into a single IHD group, we could not
differentiate between prognostic differences in relation to
severity of IHD. Previous studies have questioned whether
survival beneﬁts from CR are generalizable.36 Evidence
suggests that survival beneﬁts from CR before vascular sur-
gery are most signiﬁcant among severely affected coronary
patients.6 In addition, no difference was made on the basis
of the time between CR and the index operation. Prior
research has shown that the protective effect of CR for
adverse cardiac events diminishes as time progresses.11,37
This suggests that the demonstrated shift from IHD-
related toward non-IHD-related cardiovascular mortality
will be more apparent in vascular patients who have under-
gone recent CR. Our study could not discriminate between
CABG and PCI in survival beneﬁt analysis. Finally, strati-
ﬁed analysis for each surgical indication separately wasnot performed because of the limited event rates in the
subgroups and the consequent lack of statistical power.
CONCLUSIONS
This study adds new insights into the implications of
IHD on long-term survival in vascular surgery patients.
Our data conﬁrm the signiﬁcance of IHD for postoperative
survival of these patients as well as the effectiveness of CR
in the reduction of cardiac ischemic events. However, we
also show that treatment of IHD alone is insufﬁcient to
improve life expectancy in these high-risk patients. Patients
with prior revascularization for IHD indeed have reduced
risks of fatal cardiac ischemic events, but this does not
translate into an overall survival beneﬁt because they have
a greater risk of dying of cardiovascular causes unrelated
to IHD. Further research is warranted to determine
whether more aggressive secondary prevention regimens
are justiﬁed to prevent the shift toward non-IHD-related
health hazards and thus improve postoperative survival in
patients with advanced atherosclerotic disease.
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Supplementary Table (online only). Causes of death deﬁnitions in accordance with the International Classiﬁcation of
Diseases, Tenth Revision (ICD-10) classiﬁcation
ICD-10 Description
Cancer-related death
C00-C75 Malignant neoplasms, stated or presumed to be primary, of speciﬁed sites, except of lymphoid, hematopoietic,
and related tissue
C76-C80 Malignant neoplasms of ill-deﬁned, secondary, and unspeciﬁed sites
C81-C96 Malignant neoplasms, stated or presumed to be primary, of lymphoid, hematopoietic,
and related tissue
C97-C97 Malignant neoplasms of independent (primary) multiple sites
D00-D09 In situ neoplasms
D10-D36 Benign neoplasms
D37-D48 Neoplasms of uncertain or unknown behavior
Cardiovascular death
IHD-related cardiovascular death




I26-I28 Pulmonary heart disease and diseases of the circulatory system
I30-I49 Other forms of heart disease
I51-I52 Other forms of heart disease
I60-I69 Cerebrovascular disease
I70-I79 Diseases of arteries, arterioles, and capillaries
Chronic obstructive pulmonary disease-related death
J40-J47 Chronic lower respiratory diseases
Digestive system-related death
K00-K14 Diseases of oral cavity, salivary glands, and jaws
K20-K31 Diseases of esophagus, stomach, and duodenum
K35-K38 Diseases of appendix
K40-K46 Hernia
K50-K52 Noninfective enteritis and colitis
K55-K64 Other disease of intestines
K65-K67 Diseases of peritoneum
K70-K77 Diseases of liver
K80-K87 Disorders of gallbladder, biliary tract, and pancreas
K90-K93 Other diseases of the digestive system
IHD, Ischemic heart disease.
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